Learn About Lassa Fever

What is the definition of Lassa Fever?
Lassa fever is an acute viral, hemorrhagic (bleeding) disease mainly transmitted to humans by rats and/or food or household items contaminated with rodent urine or feces. Human-to-human transmission of Lassa fever can also occur. Lassa fever is endemic (common) in areas of West Africa.
Save information for later
Sign Up
What are the symptoms of Lassa Fever?
Most individuals (80%) who are infected with the Lassa virus do not have any symptoms or only mild symptoms. Symptoms of Lassa fever begin 1-3 weeks after infection. Mild symptoms of Lassa fever may include low fever, headache, sore throat, cough, weakness, muscle pain, and malaise. Symptoms of more severe cases of Lassa fever may include facial swelling; hair loss; gait disorder; hearing loss; encephalitis (brain inflammation); nausea and vomiting; diarrhea; fluid in the lungs; respiratory distress; tremors; chest, back, or abdominal pain; miscarriage; hemorrhaging in the eyes, nose, gums, or gastrointestinal tract; low blood pressure; shock; seizures; coma; multi-organ failure; and death. The most common complication of Lassa fever is either temporary or permanent deafness.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Lassa Fever?
Treatment for Lassa fever includes early supportive care and symptomatic treatment with adequate hydration, oxygen, blood pressure maintenance, and the antiviral drug, Ribavirin.
Who are the top Lassa Fever Local Doctors?
Elite
Elite
 
 
 
 
Learn about our expert tiers
Learn more
Elite
What are the latest Lassa Fever Clinical Trials?
A Phase 1 Randomized, Double-blinded, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults in Good General Heath

Summary: A Phase 1 Randomized, Double-blinded, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults in Good General Health

Match to trials
Find the right clinical trials for you in under a minute
Get started
Pharmacokinetics, Tolerability and Safety of Favipiravir Compared to Ribavirin for the Treatment of Lassa Fever: A Randomized Controlled Open Label Phase II Clinical Trial

Summary: This exploratory, prospective, controlled, multisite, open label, randomized clinical trial with two treatment arms aims to compare favipiravir, a new treatment candidate for Lassa fever (LF), with the current standard of care, ribavirin. The primary endpoints of this research are (1) the description of classical pharmacokinetic parameters of favipiravir in comparison with ribavirin standard treat...

What are the Latest Advances for Lassa Fever?